BioCardia, which is developing gene therapies for cardiovascular diseases, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
The San Carlos, CA-based company, which was founded in 2002 and booked $2 million in revenue for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol BCDA. BioCardia initially filed confidentially on 4/9/2015. Cantor Fitzgerald, Roth Capital and Maxim Group LLC are the joint bookrunners on the deal. No pricing terms were disclosed.